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ABSTRACT 
NICHOLAS G. BOULLARD: Cardiovascular Protective Agents and their Biochemical Role in Endothelial 
Cell Senescence 
 
Cellular senescence is a slow, biological process of aging that involves the accumulation of 
various changes to the internal environment of a cell, most notably the buildup of acidic B-
galactosidase. These changes, both structural and molecular in nature, disable metabolism of many 
cellular processes and eventually induce apoptosis. As cells divide, the ends of chromosomes, 
telomeres, slowly shorten. Once telomere shortening reaches critical levels, those chromosomes 
may no longer replicate properly, leading to cellular process complication and apoptosis. 
Telomerase is a reverse transcriptase that adds nucleotides to telomeres, elongating them and 
successfully delaying endothelial cell senescence. Endothelial cells serve an irreplaceably important 
part in our body as the thin layer of cells that line the furthest interior surface of our blood vessels. 
They are the site of reception between molecules circulating in the blood. These endothelial cells 
are the sites of many physiological processes; especially blood clotting, vasoconstriction, 
vasodilation, and inflammation. The biochemical processes of the proteins in the kinin-kallikrein 
system drive the responses of inflammation, blood pressure regulation, and blood coagulation via 
many mediators. One of the most important products, bradykinin, is generated from human plasma 
when prolylcarboxypeptidase (PRCP) converts prekallikrein (PK), bound to high molecular weight 
kininogen (HK) on the negatively charged surface of human endothelial cells. This bradykinin drives 
vasodilation as it produces nitric oxide and prostacyclin. These vasodilative properties increase 
oxygen delivery and promote further angiogenesis and delay cellular death.  Keeping this in mind, 
PRCP, as an indirect vasodilator, and basic fibroblast growth factor (FGF-2), as a promoter for 
angiogenesis, should both promote cell survival and delay endothelial cell senescence. As a control, 
B-actin and glyceraldehyde-3-phosphate dehyedrogenase (GAPDH) were used; B-actin is prevalent 
in all cells throughout their life as an integral cytoskeletal actin, and GAPDH is an important step in 
the process of glycolysis, the breakdown of glucose for energy and carbon molecules. In our results, 
we found that the activity of HK-PK peaked at Passage 18, and to support that, we found that the 
converting enzyme, PRCP, shared the same peak in activity. Our results were supported when we 
found that nitric oxide (NO), a downstream product of the PRCP-catalyzed HK-PK system, and 
endothelial nitric oxide synthase (eNOS), responsible for another method of NO production shared 
the same peak in activity as PRCP. Human telomerase reverse transcriptase (hTERT) mRNA 
concentration was examined alongside B-galactosidase (B-gal) cell staining, a universal marker for 
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cellular senescence. Our results show that the decline in hTERT precedes the onset of endothelial 
cell senescence, and that the buildup of B-gal is a sufficient indicator for the arrival of endothelial 
senescence. 
This study has emphasized the role that HK and PK play in cellular health and the delay of 
endothelial cellular senescence. We propose that nitric oxide and FGF-2 delay endothelial cell 
senescence by slowing the age-related degradation of telomerase. 
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I) INTRODUCTION 
 
A) Telomeres 
In the 1930, a geneticist named Barbara McClintock noted that DNA, as the carrier of our 
genetic information, would need to have some kind of protective mechanism at its ends in order to 
prevent the fusing and/or breakage of chromosomes during mitosis (McClintock, 1941). These 
protective  caps  went  on  to  be  called  “telomeres,”  Greek  for  “end  parts.”  The first studies on 
telomeres proved that they existed to provide stability and successful segregation of genetic 
information within cellular division. As time progressed, great advances were made in 
understanding telomeres. Telomeres are guanine-rich repetitive DNA that are maintained by their 
respective reverse-transcriptase  enzyme,  telomerase.  DNA’s  telomere  cap  is  composed  of  a  single  
strand  between  50  and  300  nucleotides,  which  has  been  proposed  to  “fold  back  onto  the  duplex  
telomeric DNA,”  forming  a  “T-loop”  structure  (Aubert and Lansdorp, 2008). As cells divide, telomeric 
DNA is lost little by little. Eventually, the closed loop unfolds, and the longer DNA strand is left 
uncopied. Over time, the telomere loss accumulates (Figure 1). Normal replication is the main cause 
for telomere loss due to the fact that DNA replication id bidirectional and DNA polymerases are 
unidirectional. DNA polymerases must initiate from a primer, and because of this, each round of 
DNA replication must leave up to two hundred base pairs unreplicated  at  the  3’  end  of  the  DNA  
(Shampay and Szostak, 1984). For a while, the telomeres are seen as salvageable, and reverse 
transcription by telomerase adds more nucleotides to the telomeres, extending their life. Once too 
many broken ends build up, the telomeres are seen as unsalvageable, and p53 sends the cell into a 
state  of  “replicative  senescence”  to  await  the  eventual  apoptosis (Shen et al., 2013).   
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Figure 1: This diagram shows the primary factors that affect telomere length in human 
somatic cells. The telomeres in younger somatic cells have long G-rich nucleotides that favor the 
folded structure. As the cells age, and telomere length decreases, the loop eventually unfolds. Once 
the ends become too short, there are various methods of DNA repair, most notably telomerase, 
which varies depending on the cell type. Eventually, too many short and broken ends will build up 
and DNA damage signals, such as p53, will signal senescence, and eventually apoptosis. (Aubert and 
Lansdorp, 2008) 
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B) Cellular Senescence 
As we age, all of our biological processes and function lose their efficiency. Age is not a direct 
cause of death, but the decreased function of our bodies, brought on by age, is. In the early 1960s, 
Leonard Hayflick observed that a culture of human tissue, in vitro, stopped dividing once the culture 
had reached an old age via numerous cellular divisions. He hypothesized that this phenomenon 
could be used to study human aging at the cellular level (Hayashi et al., 2014). Cells divide in order 
to counterbalance healthy cell loss and to repair bodily injury, but certain cells divide far more 
frequently than others. It is not uncommon to see age take place without much cellular turnover, 
but with the correlation between cellular fitness to healthy telomeres provides a sense of order to 
this conundrum. For example, telomeric DNA damage has been recorded in different human tissues 
that have aged and no longer undergo mitosis, such as the brain, heart, and kidneys. Reactive 
oxygen species (ROS), and as well as the signaling pathways of various oncogenes, have been 
documented to damage telomeric DNA effectively (Hayashi et al., 2014). As a result, it can be 
concluded that telomeric DNA damage is capable of being replication-independent, and that 
environmental predispositions to DNA damage would only exacerbate the decline in telomere 
length. The connection between telomeres and aging was established in 1986 when Cooke and 
Smith realized that the telomere repeats were significantly longer in sperm cells than adult somatic 
cells. Several studies brought the conclusion that somatic cells are simply unable to maintain 
telomere length well, and for the first time, the aging of cells could be directly linked to genomic 
DNA (Aubert and Lansdorp, 2008). 
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C) Nitric Oxide 
 One of the most outstanding studies involving cell senescence explores telomerase’s  
rejuvenation of telomeric DNA and its involvement in delaying cellular senescence. Upon further 
investigation, it is observed that the vasodilatory molecule, nitric oxide (NO), is involved in this 
reconstruction. It has been found that NO can activate telomerase and delay endothelial cell 
senescence (Donnini et al., 2010). The nitric oxide donor, S-nitroso-penicillamine (SNAP), has been 
found to significantly reduce endothelial cell senescence. Likewise, telomerase inactivation precedes 
cellular aging, but nitric oxide has been identified as being able to prevent age-related 
downregulation of telomerase activity, delaying endothelial cell senescence (Vasa et al., 2000). The 
exact mechanism with which nitric oxide prevents the downregulation of telomerase has yet to be 
determined, but it is clear that telomerase can be modulated. Some researchers believe that nitric 
oxide might react with tissue-derived oxygen radicals to reduce oxidative stress, a factor that is a 
powerful accelerator of endothelial cell senescence. Others believe that there may be a 
transcriptional/post-transcriptional mechanism by which nitric oxide could upregulate telomerase 
production. Regardless, it is known that endothelial protection is one of the main functions of nitric 
oxide (Vasa et al., 2000).  
 
D) The Circulatory System 
 As a postmitotic organ, the heart serves as an excellent subject for observing the 
degradation of telomeric DNA as it coincides with the approaching senescence. The heart, part of 
the  circulatory  system,  is  a  “four  chambered,  double  pump”  with  the  sole  purpose  to  create  the  
pressure required in order to drive our blood to the lungs, limbs, and the rest of the body (Fox, 
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1999).  The  circulatory  system,  as  a  whole,  serves  three  purposes:  “transportation,  regulation,  and  
protection.”  All  metabolites,  nutrients,  and  waste  that  the  cells  of  the  human  body  transport  are  
done so via the cardiovascular system. All of the hormonal and temperature regulation done by the 
body is accomplished through the blood. In the event of an injury or invasion of foreign 
microorganisms and toxins, the circulatory system can either respond with clotting or leukocytes 
(Fox, 1999).  
 
The other half of the circulatory system, the system of blood vessels, is a tubular network 
that carries the oxygen-rich blood from the heart to the tissues of the body in arteries before 
sending the oxygen-depleted blood back to the heart in veins. Arteries and veins are separated by 
microscopic, extremely thin capillaries, which bridge the arterial system to the venous system. This 
bridge is where the fluids, nutrients, and waste are exchanged while the blood flows from the 
smallest arteries, arterioles,  to  the  smallest  veins,  venules.  This  “tree  of  progression”  works  in  a  
nonstop, fluid motion from the heart, to the arteries, the arterioles, the capillaries, the venules, the 
veins, and then the heart again, all to be replenished (Fox, 1999). The walls of arteries and veins are 
composed of three layers, also known as tunics (Figure 2). From the outside, to the inside, they are 
“tunica  externa,  tunica  media,  and  tunica  interna.”  This  brings  us  to  the  tissue  of  our  focus:  the  
endothelium. The endothelium is the innermost layer of the innermost tunic (Fox, 1999). This 
squamous epithelium is the innermost layer of all blood vessels and it is the focus of production of 
nitric oxide and the cellular senescence which it delays. 
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Figure 2: The system of blood vessels to and from the heart (Fox, 1999). 
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E) Endothelial Nitric Oxide Synthase 
Endothelial nitric oxide plays a large role in our bodies, primarily being a mediator of 
angiogenesis,  the  formation  of  new  blood  vessels.  Nitric  oxide  is  an  endothelial  “survival  factor,”  and  
as such, it inhibits apoptosis and enhances endothelial cell proliferation/migration. As a vasodilator, 
it increases blood flow and leads to inflammation within our bodies (Cook and Losordo, 2002). Nitric 
Oxide is synthesized by the Nitric Oxide Synthanse (NOS). It is a complex enzyme that incorporates 
oxygen, arginine, and NADPH (nicotinamide adenine dinucleotide phosphate) to yield nitric oxide, 
citrulline and NADP+. This reaction is catalyzed by five separate cofactors: FMN, FAD, Heme, 
calmodulin, and tetrahydrobiopterin (Figure 3). This  process  shows  NOS’s  involvement with the 
body’s  natural  metabolism,  particularly  the  Citric  Acid  Cycle as it lies at the end of several system 
processes such as the Renin-Angiotensin System and the Kallikrein-Kinin System. 
 
 
 
 
 
Figure 3: Nitric Oxide Synthesis (Cayman Chemicals) 
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 Figure 3.1: Nitric Oxide Synthesis 
 
 
F) Plasma Kallikrein Kinin System 
To understand more about nitric oxide, it is beneficial to understand the relationship 
between the vascular Kallikrein-Kinin System and blood pressure regulation. Plasma kallikrein is a 
serine protease that liberates kinin from kininogens, plasma proteins which are converted into 
active peptides. The best known kinin, bradykinin, is our main focus when it comes to blood 
pressure regulation (Hillmeister and Persson, 2012). Bradykinin acts via two different receptors, 
bradykinin receptor one and two (B1R & B2R). Comprised by kallikrein, kininogen, kinins, and 
receptors, the Kallikrein-Kinin System (KKS) is a complex, interweaving system. Besides the discovery 
of its role in renal pathophysiology, the Kallikrein-Kinin System is important to understanding blood 
pressure homeostasis and the pathogenesis of hypertension, and other cardiovascular diseases 
(Hillmeister and Persson, 2012). 
 The plasma kinin-forming system, also known as the the Kallikrein-Kinin System (KKS), is 
comprised of three proteins: coagulation Factor XII, prekallikrien (PK), and high molecular weight 
kininogen (HK). Before the Kallikrein-Kinin System can activate, high molecular weight kininogen 
(HK) must bind to the endothelial cell surface. HK is a multifunctional, multidomain β-globulin 
protein that has a molecular weight of 120 kD, which is important when it is digested. In order for 
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HK to bind to the endothelial cell surface that, a binding site is needed, and when it comes to KKS 
and associated pathways, three binding sites have been found to be specific to endothelial cells 
(Kaplan and Ghebrehiwet, 2010). First is qC1qR, the receptor for the globular heads of C1q, the first 
component of the complement classical pathway. Besides gC1qR, there is also cytokeratin 1 and the 
urokinase plasminogen activator receptor (u-PAR). These receptors exist mostly as bimolecular 
complexes, but gC1qR can function in an uncomplexed form. Before the KKS can assemble on the 
endothelial cell surface, these surface structures must be highly, negatively charged, and the HK 
must have changed to the proper conformation via zinc (Zn2+) activation (Kaplan and Ghebrehiwet, 
2010).  
It should be pointed out that the KKS is not the only system that benefits from these binding 
complexes; the coagulation pathway and complement pathway are intertwined with the KKS. The 
KKS begins as HK binds to the gC1qR-cytokeratin 1 bimolecular complex. Meanwhile, Factor XII 
binds, temporarily, to the cytokeratin 1-u-PAR bimolecular complex long enough to go through 
autocatalytic activation. This activation converts Factor XII into Factor XIIa, activating a positive 
amplification mechanism to yield more Factor XIIa from Factor XII, but as a side effect, plasma 
prekallikrein (PK) is converted into plasma kallikrein (Ghebrehiwet and Peerschke, 2006). The newly 
convered kallikrein goes on to digest the HK in order to produce bradykinin. After moving the KKS 
pathway forward, Factor XIIa continues down its own coagulation pathway to its next substrate, 
coagulation Factor XI (Figure 4). These proteins interact through contact, activating multiple 
processes in a cascade and creating bradykinin as a cleavage product (Ghebrehiwet and Peerschke, 
2006). 
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Figure 4: This diagram shows the Kallikrein-Kinin System’s,  along  with  the  Coagulation  
Cascade, Renin-Angiotensin  System,  and  Complement  Classical  Pathways’,  roles  in  blood  pressure  
regulation (Hillmeister and Persson, 2012). 
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G) Bradykinin and its Receptors 
As a significant part of the inflammatory process, bradykinin (BK) has been observed to have 
vasodilatatory effects, hinting that it plays a protective role in the cardiovascular system. 
Specifically, BK induces vasodilation through the release of mediators from the endothelial cell 
surface, nitric oxide (NO) and prostacyclin (PGI2) (Donnini et al., 2010). Bradykinin has two receptors, 
both of which are mediated differently. The B2 kinin-receptor (B2R) is a G-protein-coupled receptor 
that is constantly expressed in a great quantity of human organs and tissues besides the 
endothelium. Through the vasodilative products of B2R, blood pressure can be regulated. On the 
other hand, the B1 kinin-receptor (B1R) is seem to be inactive under standard conditions, only to be 
expressed in the presence of bacterial endotoxins and/or cytokines, frequently hinting towards the 
existence of an infection (Dendorfer et al., 1999). BK is an invaluable tool when it comes to blood 
pressure homeostasis. 
 
H) Prolylcarboxypeptidase 
One of the more poorly-understood aspects of blood vessel homeostasis is the protein 
prolylcarboxypeptidase (PRCP). This serine protease, much like Factor XII, produces plasma kallikrein 
from plasma prekallikrein. PRCP was originally characterized as a peptidase that cleaves small, 
carboxy terminus peptides at neutral pH, but many more functions were discovered later. In 
addition, PRCP also metabolizes the interaction between BK and angiotensin II (Hagedorn, 2011). 
Only a few experiments have uncovered vital information about PRCP.  In a study on the 
hypothalamus, it was observed that the melanocortin system is affected by PRCP. Multiple studies 
have shown that mice with a PRCP enzyme deficiency have elevated melanocortin (α-MSH), leading 
to decreased food intake and weight loss. Normally, insulin (from the pancreas), and/or leptin (from 
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adipose tissue) act on anorexigenic neurosecretry cells in order to release α-MSH. This causes 
neuronal  signals  to  tell  the  body  to  “eat  less  and  metabolize  more  fuel  (Nelson, 2008). However, in 
the  presence  of  PRCP,  α-MSH is inhibited, suggesting that PRCP can be stimulate appetit. Normally, 
the  anorexigenic  α-MSH signal, stimulated from leptin and insulin, would signal the body to stop 
eating and store energy. This works so to balance out food intake and energy expenditure in the 
presence  of  the  orexigenic  “NPY”  signal,  which  tells the body to eat more (Figure 5). 
 
Figure 5: This diagram shows the arcuate nucleus (of the hypothalamus) and the process 
with which out food intake is balanced with our energy expenditure (Nelson, 2008). 
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In addition to the suggestion that PRCP functions as an appetite stimulant, it has been 
proven to have a large role in blood pressure regulation. Initially, PRCP was found to be a catalyst in 
the Renin-Angiotensin System (RAS), which also overlaps with the KKS. In renal tissues, PRCP 
controlled the amount of angiotensin II (Ang II) (Shariat-Madar et al., 2010). PRCP actively 
metabolized Ang II to angiotensin 1-7 (Ang 1-7), and the subsequent activation of the Ang 1-7 
receptor (a G-protein-coupled  receptor  similar  to  bradykinin’s  receptors)  would  yield  nitric  oxide  
and prostaglandins. Meanwhile, the inactivation  of  α-MSH by PRCP also increases the production of 
proinflammatory molecules and promotes orexigenic action (Figure 6). Due to the negative feedback 
of Ang 1-7 countering the function of Ang II, it is believed that PRCP can minimize the negative, 
vasoconstritive effects of Ang II, diminishing the occurrence of cardiovascular diseases (Shariat-
Madar et al., 2010). 
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Figure 6: This diagram shows the pathophysiological actions of the serine protease, PRCP 
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I) B-galactosidase 
Senescent cells in animals expressed increased levels of all proinflammatory molecules. This 
is interesting because it insinuates that cellular senescence contributes to the pathogenesis of 
atherosclerosis (Hayshi, et al., 2006). In order to better tie all of this together, it is important to look 
at  the  activity  of  β-galactosidase, a widely-accepted biomarker for cellular senescence. This active 
enzyme is detected using X-gal, which stains senescent cells blue in the presence of β-galactosidase. 
Acidic B-galactosidase is a eukaryotic hydrolase that is localized within the lysosome of cells. 
Because of this, its optimal processing conditions are around a pH of 4.5, although it can function 
between a pHs of 4 and 6.  (Kurz et al., 2000). 
J) Fibroblasts and Growth Factor #2 
When looking at endothelial cells, it is important to keep fibroblasts in mind. Fibroblasts 
synthesize stroma, which acts as framework, for mammalian endothelium. It does so by 
manufacturing collagen, and the extracellular matrix (Ornitz and Itoh, 2001). Fibroblast Growth 
Factor-2 (FGF-2), the alkaline fibroblast growth factor, promotes wound healing and resides 
primarily in the subendothlial layer of blood vessels, making it a perfect target for observation in the 
HPAEC cell line. As FGF-2 has been seen playing a central role in mediating angiogenesis, it has also 
been observed having a rescuing effect on impaired endothelium. Much like eNOS and hTERT, the 
up-regulation of FGF-2 has been seen to favor cellular survival and delay endothelial cell senescence 
(Donnini et al., 2010). 
K) Experimental Motivation and Reasoning 
Many factors play into endothelial growth and eventual senescence. The up-regulation of 
various pathways and their downstream products prolong the life of the average cell. Telomerase 
decreases far before senescence sets in. PRCP, FGF-2, and eNOS all reach a peak of activity where 
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their angiogenic effects combat cellular aging and death. The exact etiology of endothelial 
senescence is still generally unclear; however, studies on many genetic components, and their 
regulation, have elucidated the process of degradation. 
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II) Materials & Methods 
 
 Endothelial Cell Culture – Human pulmonary artery endothelial cells (HPAEC) were grown 
and subcultured over time, from Passage 7 to Passage 40. HPAEC were obtained and cultured in 
endothelial growth medium (EGM) from Passage 7 to Passage 40. Cells were allowed three days to 
proliferate before each subculture procedure using Trypsin, DPSB, and the trypsin neutralizing 
solution (TNS). Right before separating the cells from their flask to be subcultured, the growth 
medium was aliquoted and saved. The cells were grown in fetal bovine serum (FBS) supplemented 
EGM at a constant temperature of 36.7°C, in an environment with a constant carbon dioxide level of 
5%. The HPAEC, EGM, FBS growth supplement, HEPES, trypsin-EDTA, and trypsin neutralizing buffer 
were purchased from Clonetics (San Diego, CA). 
 
 HK/PK Activity – After obtaining a cell pellet from the trypsinized flask, the HPAEC are 
counted and calculated to ensure 30,000 cells per 100 µL well. After incubating the new cells in the 
96-well plate, overnight, they were washed with HEPES and incubated for one hour with a 1% 
HEPES-gelatin mixture to block the plate. The plate was washed twice with HEPES again before 
adding, and incubating with, 20 nM HK for one hour. The wells were washed and treated with 20 nM 
PK before being incubated for another hour. Finally, the cells were treated with 0.5 mM a HD-Pro-
Phe-Arg-paranitroanilide substrate (S2302) and incubated for an hour. All incubations took place at 
a constant temperature of 36.7°C, in an environment with a constant carbon dioxide level of 5%. 
The HK and PK were purchased from Enzyme Research Laboratory (South Bend, IN). S2302 was 
purchased from DiaPharma (Franklin, OH). After constructing the HK-PK Complex on recently 
subcultured cells in a 96-well plate, the activity of plasma kallikrein was quantified by detecting the 
amount of free paranitroanilide in vitro, at 405 nm using the ELx800 Plate Reader (Bio-Tek). 
 
 Western Blot – Adherent cell monolayer were washed with DPSB. The protein cell lysates 
were extracted using the RiPA Buffer (Thermo Scientific) and separated by electrophoresis in a 10% 
acrylamide  gel;  the  standard  used  was  the  “Precision  Plus  Protein”  standard,  Dual  Color  from  Bio-
Rad (Cat. 161-0374). After electrophoresis, the gel was transferred to a nitrocellulose membrane in 
a buffer consisting of methanol, diH2O, and 10x Tris/glycine buffer at 4 °C for one hour. Once 
transferred, the membrane was blocked for one hour with 5% non-fat, dry milk in PBS with 0.1% 
Tween-20 (PBST). Then, the membrane is treated overnight at 4 °C with the primary antibody, Goat 
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Anti-Human PRCP (Bioscience), made in a 1:20 dilution. The next day, the membrane was washed 
thrice with PBST and then treated with a secondary antibody, Anti-Goat IgG: Whole Molecule, 
Peroxidase Conjugate (Bioscience), made in a 1:1000 dilution. The membrane was washed thrice 
again with PBST  before  being  treated  with  the  “Super  Signal  West  Femto  Maximum  Sensitivity  
Substrate,”  courtesy  of  Thermo  Scientific  (Rockford,  IL),  a  chemiluminescent  substrate  to  be  used  for  
imaging with the ChemiDoc Imager (Bio-Rad).  
 Following the first set of imaging, the membrane was washed with 1x PBS and stripped with 
Thermo  Scientific’s  “Restore  Western  Blot  Stripping  Buffer”  at  room  temperature  for  15  minutes  
before being blocked again and treated with the primary antibody, Mouse Anti-Human B-Actin 
(Santa Cruz, Cat. sc-49272) made in a 1:100 dilution, and the secondary antibody, was Anti-Goat IgG: 
Whole Molecule, Peroxidase Conjugate (Bioscience) made in a 1:1000 dilution. After blocking, 
treating, and washing, the membrane was imaged again and a ratio between the two densities was 
calculated. 
 
Nitrite/Nitrate Assay – Growth medium was collected and stored over the course of growing 
HPAEC  passages.  The  “Nitrate/Nitrite  Fluorometric  Assay  Kit”  (Cayman  Chemicals)  was  used  to  
quantify the metabolites of endothelial nitric oxide. Samples of used growth medium were adjusted 
to 80 µL with a 50/50 mix of fresh growth medium and Assay Buffer. Enzyme Cofactors and Nitrate 
Reductase was added to each well and the plate was incubated for an hour at room temperature. 
Afterwards, DAN (2,3-diaminoaphthalene) was added, followed by sodium hydroxide. The plate was 
read, and using the standard curve, the concentration of Nitrate + Nitrite was calculated. 
 
Cellular Senescence Assay Kit – The  “Chemicon  International”  Cellular  Senescence Assay Kit 
was used on various passages of growing HPAEC cells to qualify their percentage of senescent cells. 
Senescent-associated  β-galactosidase (SA-β-gal)  is  only  present  in  senescent  cells,  and  Chemicon’s  
kit provides all reagents needed to detect SA-β-gal activity at pH 6.0 in cell cultures. SA-β-gal 
catalyzes the hydrolysis of X-gal, causing the accumulation of the blue dye in senescent cells. 
 
Reverse-Transcriptase Polymerase Chain Reaction and Agarose Gel – Cell pellets were 
resuspended using TRIzol (Life Technologies). The mRNA was extracted from subcultured HPAEC 
using QIAGEN’s  “RNase-Free  DNase  Set.”  RNA  was  put  through  reverse-transcription  via  Invitrogen’s  
“SuperScript  III  One-Step RT-PCR  (with  Platinum  Taq)  Kit.”  We  bought  multiple  human  DNA primers 
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from Invitrogen, including hTERT (SENSE – 5’  ATG  GGG  ACA  TGG  AGA  ACA  AG  3’  and  ANTISENSE  – 5’  
GTG  AAC  CTG  CGG  AAG  ACG  GT  3’),  B-Actin (SENSE – 5’  TGA  ATG  GAC  AGC  CAT  CAT  GGA  C  3’  and  
ANTISENSE – 5’  TCT  CAA  GTC  AGT  GTA  CAG  GAA  AGC  3’),  FGF-2 (SENSE – 5’  TCA  GCT  CTT  AGC  AGA  
CAT  TGG  AAG  AAA  AAG  3’  and  ANTISENSE  – 5’  GGA  GTG  TGT  GCT  AAC  CGT  TAC  CTG  GCT  ATG  3’),  
PRCP (SENSE – 5’  GTG  GCT  GAG  GAA  CTG  AAA  GC  3’  and  ANTISENSE  – 5’  TGT  CAC  CAA  AGG  GGA  
GAG  AC  3’)  ,  and  eNOS (SENSE – 5’  ATG  TTT  GTC  TGC  GGC  GAT  GTT  AC  3’  and  ANTISENSE  – 5’  ATG  
CGG  CTT  GTC  ACT  TCC  TG  3’). The agarose gel varied in concentration from 1% to 2% depending on 
the primer under observation. We purchased Agarose powder from Invitrogen and ethidium 
bromide from Sigma.  
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III) EXPERIMENTATIONS 
 
A) Plasma Kallikrein Activity  
 As Human Pulmonary Artery Endothelial Cells (HPAEC) Age, Plasma Kallikrein (PK) Activity 
Increases, Until Reaching a Peak before Tapering Off – The binding of high molecular weight 
kininogen (HK) has been described previously. Because the Kallikrein-Kinin System (KKS) has been 
discovered to be linked to regulation of blood pressure, among many other protective effects, we 
decided to measure the activation of PK from the complex of HK and plasma prekallikrein by 
detecting the absorbance of freed PNA from S2302 (Dendorfer, Wolfrun, & and Dominiak, 1999). 
The HPAEC were subcultured repeatedly, from Passage 7 to Passage 40 in order to show a gradual 
decrease into cellular senescence. Our results yielded that PK Activity does increase over time, 
peaking at Passage #18. After Passage 18, the PK activity decreases, gradually.  
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Figure 7: The formation of Plasma Kallikrein is measured from the High Molecular Weight Kininogen-
Plasma Prekallikrein Complex. The absorbance of paranitroanilide, cleaved by activated kallikrein, 
was measured at 405 nanometers. 
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We know that Factor XII catalyzes the release of PK from the HK-PK Complex, but so does 
prolylcarboxypeptidase (PRCP). We can infer that the trend exhibited by the HK-PK activity should 
match the trend of PRCP activity.  
 
B) PRCP Protein Expression  
 PRCP Expression Coincides with HK-PK Activation – After performing multiple Western Blots 
to measure protein expression of PRCP, it was found that a trend similar to HK-PK Activity can be 
found. PRCP expression increases from Passages 11 and 17 to peak at Passages 18 and 19, followed 
by a significant decrease in Passage 25 (Figure 8). 
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Figure 8: First, PRCP Expression was measured in various HPAEC. The expression of the target 
protein was quantified and then a ratio was normalized between PRCP and a cellular structure, 
control  protein  β-actin. 
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This trend of PRCP expression is logical due to the fact that  one  of  PRCP’s  many  roles  is  to  produce  
PK from plasma prekallikrein (Peerschke, 2006). After treating and imaging the membrane with anti-
PRCP, the membrane was stripped and treated with anti-B-Actin, in order to provide a normalized 
and accurate set of results.  
 
C) Nitric Oxide Product Fluorometry 
 Nitric Oxide Detection via Fluorometric Assay Agrees with PRCP Expression – The final 
products of NO, in vivo, are nitrite (NO2-) and nitrate (NO3-) (Figure 9). Due to the fact that they are 
produced in random proportions, the most accurate way to measure total NO production is to 
measure the sum of both nitrate and nitrite. The NO quantification can be completed in two steps. 
First, nitrate is converted to nitrite via nitrate reductase. Second, acidic DAN (2,3-
diaminonaphthalene) is added. Sodium hydroxide, which enhances detection of 1(H)-
naphthotriazole (the fluorescent product), is added last (Figure 10).  
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Figure 9: A series of simplified, unbalanced reactions involving NO and various molecules in vivo, 
and brief explanations of those reactions. 
 
 
 
 
Figure 10: The chemistry behind the fluorescence of nitric oxide metabolites and their detection. 
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 Nitric Oxide Production Mimics the Pattern of PRCP Activity –Understandably, as the cell 
passage increased, so did the amount of NO products. This supports the findings of the previous 
PRCP protein detection. As NO is a downstream product of PRCP, and a vasodilative, protective 
molecule, the peak would be expected around P17, 18, and 19, as is seen with PRCP (Figure 11). 
 
 
 
Figure 11: The products of nitric oxide, nitrate and nitrite, measured over time. Similarly to the 
quantification of PRCP, NO products also peak later before experiencing a drop in activity. 
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D) Endothelial Nitric Oxide Synthase DNA Expression  
 eNOS DNA Quantification Mimics NO Detection – After quantifying the amount of nitric 
oxide product, the next logical step would be to quanitify the amount of endothelial nitric oxide 
synthase (eNOS). After measuring the products of NO, mRNA from the same HPAEC cell lines was 
extracted and put through reverse transcriptase polymerase chain reaction (RT-PCR) with a primer 
for endothelial nitric oxide synthase. This would enable us to quantify the amount of eNOS present 
in cell passages over time. Our results supported previous findings with NO, showing that there is a 
rapid increase in eNOS over time, followed by a slow decrease (Figure 12). This slow decrease is due 
to the rising need for NO to oxidize the increased quantity of reactive oxygen species. As NO is 
rapidly used up, eNOS remains steady for several late, senescent passages  
 
  
 
Figure 12: The sustained peak in eNOS supports the findings that nitric oxide delays endothelial cell 
senescence. 
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E) B-Galactosidase Staining and Relative Cell Count 
 B-Galactosidase Activity Increases With Age – In order to better visualize the effect of aging 
on  endothelial  cell  senescence,  β-Galactosidase staining was implemented on various HPAEC 
passages. As cells age, their concentration of B-galactosidase increases, as the staining reveals. 
Relative cell count was measured and graphed (Figure 13). As a universal marker for endothelial cell 
senescence, the increase in B-galactosidase is expected to coincide with a decrease in telomerase 
(hTERT). 
 
 
 
 
P8 
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Figure 13: B-galactosidase staining was performed on various HPAEC cell passages. Using the 
microscope’s  camera,  pictures  were  taken  of  each  passage, and relative B-galactosidase-positive cell 
percentage was calculated. 
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F) Human Telomerase Reverse Transcriptase mRNA Expression 
 hTERT DNA Quantification Shows Steady Decrease Over Time – Senescence, detectable 
through B-galactosidase staining, is triggered by constant shortening of telomeres; therefore, it can 
be delayed by telomersase. After staining for B-galactosidase, mRNA from the same HPAEC cell lines 
was extracted and put through reverse transcriptase polymerase chain reaction (RT-PCR) with a 
primer for human telomerase reverse transcriptase. Our observations show that as hTERT 
decreases, B-galactosidase increases. In fact, no B-gal is detected until hTERT reaches minimal levels 
(Figure 14). It can be concluded that hTERT delays endothelial cell senescence via its function of 
elongation of telomeres. 
 
 
 
 
 
 
 
 
 
Figure 14: Telomerase decline precedes endothelial cell senescence. 
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G) Prolylcarboxpeptidas mRNA Expression 
 PRCP DNA Quantification Mimics PRCP Protein Quantification – In order to further look into 
PRCP, we extracted mRNA from the same cells that we extracted lysis to analyze the protein. We 
used RT-PCR and quantified the DNA. Our results show that PRCP follows the same trend as seen 
before, reaching maximum activity around Passages 17 and 18 (Figure 15). 
 
 
 
 
 
Figure 15: PRCP DNA follows the same trend as PRCP Protein, further supporting the evidence of 
PRCP playing a cardioprotective role via senescence delay. 
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H) Fibroblast Growth Factor-2 mRNA Expression 
 FGF-2 DNA Quantification Mimics PRCP – After looking into many facets of study pertaining 
to angiogenesis and cardiovascular health, it was a logical continuation to add a study of fibroblasts 
to the experiments. Fibroblast growth factor #2 is responsible for cell survival and the formation of 
new blood vessels. Keeping this in mind, we would expect it to flourish with the up-regulation of 
PRCP and other angiogenic molecules. FGF-2 mimicked PRCP, peaking slightly earlier, but followed 
the same trend as PRCP, reinforcing the belief that, it too, promotes cell survival and the delay of 
endothelial cell senescence (Figure 16.) 
 
 
 
 
Figure 16: FGF-2 promotes cellular survival, proliferation, and angiogenesis 
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IV) DISCUSSION 
 The plasma kallikrein kinin system plays a major role in inflammation and blood pressure 
regulation via its unique blood proteins. By investigating the origin complex of this system, 
comprised of HK and PK, we found a great starting point to investigate cardioprotective effects on 
senescence. PRCP, found to promote cardiovascular protection through many facets of autophagy, 
was observed in multiple forms, and a causal relationship was found between kallikrein activity and 
PRCP. When measuring PRCP protein concentration, B-actin was used as a cellular control in order 
to provide normalization of our results. After investigating the origins of the KKS, we decided to 
follow the pathway to the end. Quantifying the NO product would be necessary. As a downstream 
product, the highly reactive NO was successfully quantified from old growth medium in the form of 
its metabolites. In order to verify the validity of our NO product, a second source of the molecule 
was observed, the B2R-mediated eNOS. Our findings show that as senescence onset occurs, the 
need for NO rises rapidly, and for a while, eNOS activity  maintains its peak level of expression to 
meet that need; however, decreasing levels of arginine eventually render eNOS inactive. 
 As a universal marker for  senescence,  observation  of  β-galactosidase was crucial when 
observing the decrease in hTERT over time. We  knew  β  -gal would increase over time, and previous 
articles supported the idea of hTERT degradation being the penultimate step to the onset of cellular 
senescence. Our findings support that hypothesis. In order to be sure, we used GAPDH, a cellular 
control, when measuring hTERT, to provide normalization of our results. The inclusion of FGF-2, due 
to being a major source of angiogenesis, incorporated variety and allowed us to observe other types 
of cardioprotective proteins. The results from the FGF-2 study supported our previous findings and 
showing a senescence inhibiting effect via the Passage 15 peak. 
 Our data shows that the PRCP-mediated kallikrein kinin pathway delays endothelial cell 
senescence by promoting cellular survival through generation of vasodilative molecules, like nitric 
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oxide. In addition, the  increase  in  β-gal coincides with not only the progression of senescence, but 
also the peak, and subsequent decrease, in PRCP and FGF-2 expression patters.  Also, our data 
supports the idea of the decrease in hTERT initiating a change in the PRCP-induced PK activation, 
leading to the onset of senescence.  In conclusion, to the PRCP is believed to play a role in 
autophagy and blood protein activation in order to extend the life of endothelial cells. The 
interplaying relations ship between the kallikrein kinin system, renin angiotensin system, and other 
associated pathways is shown in Figure 17 (gC1qR = globular C1q receptor, CK1 = cytokeratin 1, 
uPAR = urokinase plasminogen activator receptor, PK = prekallikrein, HK = high molecular weight 
kininogen, KA = activated kallikrein, HKa = high molecular weight kiniogen a, PRCP = 
prolylcarboxypeptidase, BK = bradykinin, BK1-8 = des-Arg-bradykinin, KD = kallidin (lys-bradykinin), 
B2R = constitutive bradykinin receptor, eNOS = endothelial nitric oxide synthase, B1R = inducible 
bradykinin receptor, iNOS = inducible nitric oxide synthase, NO = nitric oxide, Arg = arginine, Cit = 
citrulline,, FGF-2 = fibroblast growth factor #2, hTERT = Human Telomerase Reverse Transcriptase 
(hTERT),  α-MSH = alpha-melanocyte  stimulating  hormone,  β-gal = beta-galactosidase, Ang = 
angiotensin, MR = mass receptors.) 
. 
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Figure 17: A chart summarizing the various causes of vasodilation, angiogenesis, and cell 
proliferation, and their involvement with the onset of endothelial cell senescence. (*Æ induced by 
tissue damage/inflammation, + Æ activates, - Æ inhibits) 
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